Abstract

Marburg and Ebola filoviruses are two of the deadliest infectious agents and several outbreaks have occurred in the last decades. Although several receptors and co-receptors have been reported for Ebola virus, key host factors remain to be elucidated. In this study, using a haploid cell screening platform, we identify the guanine nucleotide exchange factor CCZ1 as a key host factor in the early stage of filovirus replication. The critical role of CCZ1 for filovirus infections is validated in 3D primary human hepatocyte cultures and human blood-vessel organoids, both critical target sites for Ebola and Marburg virus tropism. Mechanistically, CCZ1 controls early to late endosomal trafficking of these viruses. In addition, we report that CCZ1 has a role in the endosomal trafficking of endocytosis-dependent SARS-CoV-2 infections, but not in infections by Lassa virus, which enters endo-lysosomal trafficking at the late endosome stage. Thus, we have identified an essential host pathway for filovirus infections in cell lines and engineered human target tissues. Inhibition of CCZ1 nearly completely abolishes Marburg and Ebola infections. Thus, targeting CCZ1 could potentially serve as a promising drug target for controlling infections caused by various viruses, such as SARS-CoV-2, Marburg, and Ebola.

Host factors involved in filovirus infection are incompletely understood. Here, the authors used a haploid cell screening system to unveil CCZ1’s crucial role in regulating endosomal trafficking thus virus movement within cells and thereby impacting Marburg and Ebola infection.

Details

Title
Identification of CCZ1 as an essential lysosomal trafficking regulator in Marburg and Ebola virus infections
Author
Monteil, Vanessa 1   VIAFID ORCID Logo  ; Kwon, Hyesoo 2   VIAFID ORCID Logo  ; John, Lijo 2 ; Salata, Cristiano 3   VIAFID ORCID Logo  ; Jonsson, Gustav 4   VIAFID ORCID Logo  ; Vorrink, Sabine U. 5 ; Appelberg, Sofia 6   VIAFID ORCID Logo  ; Youhanna, Sonia 5 ; Dyczynski, Matheus 7 ; Leopoldi, Alexandra 8 ; Leeb, Nicole 8 ; Volz, Jennifer 8 ; Hagelkruys, Astrid 8   VIAFID ORCID Logo  ; Kellner, Max J. 4 ; Devignot, Stéphanie 1   VIAFID ORCID Logo  ; Michlits, Georg 9   VIAFID ORCID Logo  ; Foong-Sobis, Michelle 8 ; Weber, Friedemann 10   VIAFID ORCID Logo  ; Lauschke, Volker M. 11   VIAFID ORCID Logo  ; Horn, Moritz 12 ; Feldmann, Heinz 13   VIAFID ORCID Logo  ; Elling, Ulrich 8   VIAFID ORCID Logo  ; Penninger, Josef M. 14   VIAFID ORCID Logo  ; Mirazimi, Ali 15   VIAFID ORCID Logo 

 Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
 National Veterinary Institute, Uppsala, Sweden (GRID:grid.419788.b) (ISNI:0000 0001 2166 9211) 
 University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470) 
 Institute of Molecular Biotechnology of the Austrian Academy of Science, IMBA, Vienna, Austria (GRID:grid.417521.4) (ISNI:0000 0001 0008 2788); Doctoral School of the University of Vienna and Medical University of Vienna, Vienna BioCenter PhD Program, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492) 
 Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Public Health Agency of Sweden, Solna, Sweden (GRID:grid.419734.c) (ISNI:0000 0000 9580 3113) 
 Acus Laboratories GmbH, Cologne, Germany (GRID:grid.4714.6); JLP Health GmbH, Vienna, Austria (GRID:grid.4714.6) 
 Institute of Molecular Biotechnology of the Austrian Academy of Science, IMBA, Vienna, Austria (GRID:grid.417521.4) (ISNI:0000 0001 0008 2788) 
 Acus Laboratories GmbH, Cologne, Germany (GRID:grid.24381.3c); JLP Health GmbH, Vienna, Austria (GRID:grid.24381.3c) 
10  Justus Liebig University, Institute for Virology, FB10-Veterinary Medicine, Giessen, Germany (GRID:grid.8664.c) (ISNI:0000 0001 2165 8627) 
11  Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); University Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (GRID:grid.502798.1) (ISNI:0000 0004 0561 903X) 
12  Acus Laboratories GmbH, Cologne, Germany (GRID:grid.502798.1); JLP Health GmbH, Vienna, Austria (GRID:grid.502798.1) 
13  National Institutes of Health, Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
14  Institute of Molecular Biotechnology of the Austrian Academy of Science, IMBA, Vienna, Austria (GRID:grid.417521.4) (ISNI:0000 0001 0008 2788); University of British Columbia, Department of Medical Genetics, Life Sciences Institute, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); Medical University of Vienna, Department of Laboratory Medicine, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492); Helmholtz Centre for Infection Research, Braunschweig, Germany (GRID:grid.7490.a) (ISNI:0000 0001 2238 295X) 
15  Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); National Veterinary Institute, Uppsala, Sweden (GRID:grid.419788.b) (ISNI:0000 0001 2166 9211); Public Health Agency of Sweden, Solna, Sweden (GRID:grid.419734.c) (ISNI:0000 0000 9580 3113) 
Pages
6785
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2881543761
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.